<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017743</url>
  </required_header>
  <id_info>
    <org_study_id>TREBECA</org_study_id>
    <nct_id>NCT02017743</nct_id>
  </id_info>
  <brief_title>Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism</brief_title>
  <acronym>TREBECA</acronym>
  <official_title>Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism - An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trio Grup Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trio Grup Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter post authorization observational study. Cancer patients diagnosed&#xD;
      with non high risk VTE and are followed up in an outpatient setting will be treated with LMWH&#xD;
      and the data will be recorded. Since this is an observational study there are no specific&#xD;
      treatment protocols, i.e., patients will be treated according to the best investigator's&#xD;
      criteria. Treatment protocol will be based on the routine treatment practice of the involved&#xD;
      investigator. Patients to enroll will be cancer patients diagnosed for VTE and who are able&#xD;
      to receive outpatient LMWH treatment. There will be no specific hypothesis to be tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria&#xD;
&#xD;
        -  18 years or upper age&#xD;
&#xD;
        -  A signed informed consent document&#xD;
&#xD;
        -  Cancer patient diagnosed for VTE&#xD;
&#xD;
        -  Life expectancy &gt; 6 months&#xD;
&#xD;
        -  Eligible for criteria of outpatient administration of LMWH&#xD;
&#xD;
      Exclusion criteria&#xD;
&#xD;
      • Should not carry any medical situation listed below, that outpatient administration of LMWH&#xD;
      might be risky :&#xD;
&#xD;
        1. Patients with active bleeding or at-risk for bleeding&#xD;
&#xD;
        2. Major surgery in the last 7 days&#xD;
&#xD;
        3. Cardiopulmonary unstability&#xD;
&#xD;
        4. Severe systemic venous occlusion&#xD;
&#xD;
        5. Patients at high risk for pulmonary embolism&#xD;
&#xD;
        6. Thrombocytopenia (&lt;50000/microliter)&#xD;
&#xD;
        7. Inpatients under medical or surgery supervision&#xD;
&#xD;
        8. Patients with low ability to communicate and for whom it is not possible to provide care&#xD;
           at home&#xD;
&#xD;
        9. INR≥1.5 due to liver functions impairment&#xD;
&#xD;
       10. Diagnosed for cerebral vascular aneurism&#xD;
&#xD;
       11. Active gastric and/or duodenum ulcer&#xD;
&#xD;
       12. Diagnosed for bacterial endocarditis&#xD;
&#xD;
       13. Severe renal function impairment (Creatinine clearance &lt; 30 ml/min)&#xD;
&#xD;
       14. Grade 3 hypertension (DBP &gt;= 110 mmHg and/or SBP &gt;= 180 mmHg)&#xD;
&#xD;
       15. &lt;35 kg or ≥110 kg weight&#xD;
&#xD;
       16. Known allergy to heparin and/or its derivatives&#xD;
&#xD;
       17. History of cerebrovascular event in the last 1 month&#xD;
&#xD;
       18. Active haemorrhage within the last 3 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of effectiveness of LMWH used in the treatment of thrombosis in cancer patients with VTE regarding new thrombosis.</measure>
    <time_frame>[Time to new thrombosis in 15 days]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of effectiveness of LMWH used in the treatment of thrombosis in cancer patients with VTE regarding resolution.</measure>
    <time_frame>[Time to resolution in 15 days]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of effectiveness of LMWH used in the treatment of thrombosis in cancer patients with VTE regarding bleeding</measure>
    <time_frame>[Time to bleeding in 15 days]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Venous Thromboembolism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients to enroll will be cancer patients diagnosed for VTE and who are able to receive&#xD;
        outpatient LMWH treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or upper age&#xD;
&#xD;
          -  A signed informed consent document&#xD;
&#xD;
          -  Cancer patient diagnosed for VTE&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Eligible for criteria of outpatient administration of LMWH&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active bleeding or at-risk for bleeding&#xD;
&#xD;
          -  Major surgery in the last 7 days&#xD;
&#xD;
          -  Cardiopulmonary unstability&#xD;
&#xD;
          -  Severe systemic venous occlusion&#xD;
&#xD;
          -  Patients at high risk for pulmonary embolism&#xD;
&#xD;
          -  Thrombocytopenia (&lt;50000/microliter)&#xD;
&#xD;
          -  Inpatients under medical or surgery supervision&#xD;
&#xD;
          -  Patients with low ability to communicate and for whom it is not possible to provide&#xD;
             care at home&#xD;
&#xD;
          -  INR≥1.5 due to liver functions impairment&#xD;
&#xD;
          -  Diagnosed for cerebral vascular aneurism&#xD;
&#xD;
          -  Active gastric and/or duodenum ulcer&#xD;
&#xD;
          -  Diagnosed for bacterial endocarditis&#xD;
&#xD;
          -  Severe renal function impairment (Creatinine clearance &lt; 30 ml/min)&#xD;
&#xD;
          -  Grade 3 hypertension (DBP &gt;= 110 mmHg and/or SBP &gt;= 180 mmHg)&#xD;
&#xD;
          -  &lt;35 kg or ≥110 kg weight&#xD;
&#xD;
          -  Known allergy to heparin and/or its derivatives&#xD;
&#xD;
          -  History of cerebrovascular event in the last 1 month&#xD;
&#xD;
          -  Active haemorrhage within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Metin Ozkan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erciyes University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Metin Ozkan, Prof</last_name>
    <email>metino@erciyes.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilker Kurkcu, Pharm</last_name>
    <email>ilker.kurkcu@triogrup-cro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erciyes University Faculty of Medicine</name>
      <address>
        <city>Kayseri</city>
        <state>Melikgazi</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Metin Ozkan, Prof</last_name>
      <email>metino@erciyes.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Metin Ozkan, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

